Veerhealth Care has scheduled its 34th Annual General Meeting for Wednesday, September 23, 2026. The event will be conducted through video conferencing or other audio-visual means at 4:00 pm.

Meeting Details

The company notified the BSE Limited on August 31, 2026, regarding the upcoming shareholder meeting. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Notice of the 34th Annual General Meeting along with the Annual Report for FY26 will be made available on the company website at www.veerhealthcare.net .

Regulatory Compliance

Pursuant to Regulation 36(1)(b) of the SEBI Listing Regulations, the company sent letters containing the web link to the annual report to members without registered email IDs as of August 21, 2026.

Shareholders holding physical securities are reminded to update their KYC details, including PAN, bank account information, and nomination choices, in accordance with SEBI Master Circular No. SEBI/HO/MIRSD/POD-1/P/CIR/2024/37. Payments for folios lacking updated details will be made only via electronic mode.

Veerhealth Care reported a 38% year-on-year increase in net profit to ₹54.40 lakh for the financial year ended March 31, 2026. Revenue from operations more than doubled, rising 95% to ₹3,248.45 lakh, driven by expanded third-party manufacturing and export activities.

The company's top-line growth was supported by securing US FDA registration, which unlocked bulk export orders. This operational expansion led to higher stock movement and improved inventory turnover ratios during the period.

Financial Performance

Revenue from operations surged to ₹3,248.45 lakh in FY26, compared to ₹1,667.05 lakh in the previous year. EBITDA expanded significantly to ₹326.34 lakh from ₹167.95 lakh a year earlier, reflecting stronger operational leverage despite rising input costs.

Profit before tax stood at ₹125.79 lakh, up from ₹50.78 lakh in FY25. However, this figure was impacted by an exceptional item of ₹30.99 lakh, classified as a foreign exchange loss due to INR depreciation against the USD on outstanding borrowings.

What the Numbers Show

The divergence between operating performance and other income highlights the structural shift in the company's earnings profile. While EBITDA nearly doubled, other income fell 34% to ₹80.16 lakh from ₹121.87 lakh, primarily due to lower interest income on loans and bank balances (₹42.23 lakh vs ₹60.53 lakh). Consequently, net profit grew at a slower pace (38%) than EBITDA (94%), indicating that core operations are becoming the dominant driver of profitability rather than financial assets.

Balance Sheet and Capital Structure

Total assets rose to ₹44.17 crore from ₹33.77 crore. Current assets increased sharply to ₹18.48 crore, driven by a rise in trade receivables to ₹9.74 crore and inventories to ₹4.45 crore. This was funded by an increase in trade payables to ₹12.12 crore, reflecting better credit terms from suppliers.

Net worth improved to ₹22.92 crore from ₹22.22 crore. The company did not declare any dividend for FY26, opting to retain earnings for further expansion and working capital requirements.

Corporate Developments

The Board approved the issuance of fully convertible warrants to promoters and non-promoters to raise funds for business expansion. Executive Director Mrs. Shruti A. Shah retires by rotation at the upcoming AGM on September 23, 2026, and offers herself for re-appointment. No dividend was recommended for the year.